SE9400088D0
(sv)
*
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
US6740734B1
(en)
|
1994-01-14 |
2004-05-25 |
Biovitrum Ab |
Bacterial receptor structures
|
US5939404A
(en)
*
|
1995-12-27 |
1999-08-17 |
Ngk Insulators, Ltd. |
Cancer metastasis inhibitor containing a streptococcus agalactiae Ia type or Ib type surface polysaccharide as a main ingredient
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
SE9704141D0
(sv)
*
|
1997-11-12 |
1997-11-12 |
Sbl Vaccin Ab |
New protein and nucleotide sequence, encoding said protein
|
GB9823071D0
(en)
*
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
US6602977B1
(en)
*
|
1999-04-19 |
2003-08-05 |
Biovitrum Ab |
Receptor structures
|
SE9901379D0
(sv)
*
|
1999-04-19 |
1999-04-19 |
Pharmacia & Upjohn Ab |
Receptor structures
|
CA2374013A1
(en)
*
|
1999-05-15 |
2000-11-23 |
University Of California, San Diego |
Protein a based binding domains with desirable activities
|
US7163686B1
(en)
|
1999-05-15 |
2007-01-16 |
The Regents Of The University Of California |
Protein A based binding domains with desirable activities
|
GB9917027D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
DE60030323T2
(de)
*
|
1999-12-24 |
2007-10-11 |
Genentech, Inc., South San Francisco |
Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
|
GB0017720D0
(en)
*
|
2000-07-19 |
2000-09-06 |
Got A Gene Ab |
Modified virus
|
JP2005504261A
(ja)
*
|
2001-01-12 |
2005-02-10 |
アフィボディ・アーベー |
検出方法
|
US20040077017A1
(en)
*
|
2001-01-12 |
2004-04-22 |
Amelie Karlstrom |
Detection methods
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
EP1390535B1
(de)
*
|
2001-04-26 |
2010-06-30 |
Amgen Mountain View Inc. |
Kombinatorische bibliotheken von monomerdomänen
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
FI115343B
(fi)
*
|
2001-10-22 |
2005-04-15 |
Filtronic Lk Oy |
Sisäinen monikaista-antenni
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20040009530A1
(en)
*
|
2002-01-16 |
2004-01-15 |
Wilson David S. |
Engineered binding proteins
|
SE0200943D0
(sv)
*
|
2002-03-25 |
2002-03-25 |
Amersham Biosciences Ab |
Mutant protein
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
CN1678634A
(zh)
*
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US20050074865A1
(en)
|
2002-08-27 |
2005-04-07 |
Compound Therapeutics, Inc. |
Adzymes and uses thereof
|
WO2004076678A2
(en)
*
|
2003-02-24 |
2004-09-10 |
Pritest, Inc. |
Translucent solid matrix assay device for microarray analysis
|
US6861251B2
(en)
|
2003-02-24 |
2005-03-01 |
Pritest, Inc. |
Translucent solid matrix assay device for microarray analysis
|
US20060177870A1
(en)
*
|
2003-04-28 |
2006-08-10 |
Ciphergen Biosystems, Inc |
Immunoassays
|
EP2829283B1
(de)
|
2003-04-30 |
2017-06-07 |
Universität Zürich |
Verfahren zur Behandlung von Krebs unter Verwendung eines Immuntoxins
|
US7993650B2
(en)
*
|
2003-07-04 |
2011-08-09 |
Affibody Ab |
Polypeptides having binding affinity for HER2
|
US7956165B2
(en)
|
2003-07-24 |
2011-06-07 |
Affisink Biotechnology Ltd. |
Compositions and methods for purifying and crystallizing molecules of interest
|
IL157086A0
(en)
*
|
2003-07-24 |
2004-02-08 |
Guy Patchornik |
Multivalent ligand complexes
|
US20050181398A1
(en)
*
|
2004-01-16 |
2005-08-18 |
Fung Eric T. |
Specific detection of host response protein clusters
|
EP2380594B1
(de)
|
2004-04-06 |
2019-12-04 |
Affibody AB |
Verwendung eines serumalbumin-bindenden peptide zur reduzierung des immunogenität eines proteins
|
US8512219B2
(en)
|
2004-04-19 |
2013-08-20 |
The Invention Science Fund I, Llc |
Bioelectromagnetic interface system
|
US8024036B2
(en)
|
2007-03-19 |
2011-09-20 |
The Invention Science Fund I, Llc |
Lumen-traveling biological interface device and method of use
|
US7850676B2
(en)
|
2004-04-19 |
2010-12-14 |
The Invention Science Fund I, Llc |
System with a reservoir for perfusion management
|
US8092549B2
(en)
|
2004-09-24 |
2012-01-10 |
The Invention Science Fund I, Llc |
Ciliated stent-like-system
|
US7998060B2
(en)
|
2004-04-19 |
2011-08-16 |
The Invention Science Fund I, Llc |
Lumen-traveling delivery device
|
US9011329B2
(en)
|
2004-04-19 |
2015-04-21 |
Searete Llc |
Lumenally-active device
|
US8337482B2
(en)
|
2004-04-19 |
2012-12-25 |
The Invention Science Fund I, Llc |
System for perfusion management
|
US8000784B2
(en)
|
2004-04-19 |
2011-08-16 |
The Invention Science Fund I, Llc |
Lumen-traveling device
|
US8361013B2
(en)
|
2004-04-19 |
2013-01-29 |
The Invention Science Fund I, Llc |
Telescoping perfusion management system
|
US8353896B2
(en)
|
2004-04-19 |
2013-01-15 |
The Invention Science Fund I, Llc |
Controllable release nasal system
|
WO2005118642A2
(en)
*
|
2004-06-01 |
2005-12-15 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
RU2401842C2
(ru)
|
2004-10-08 |
2010-10-20 |
Домантис Лимитед |
Антагонисты и способы их применения
|
CA2589800A1
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
CA2593956A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Lipopeptide Ab |
Agents inhibiting the cathelin-like protein cap18/ll-37
|
US20070003528A1
(en)
|
2005-06-29 |
2007-01-04 |
Paul Consigny |
Intracoronary device and method of use thereof
|
US20100028358A1
(en)
|
2005-11-07 |
2010-02-04 |
Wolfram Ruf |
Compositions and Methods for Controlling Tissue Factor Signaling Specificity
|
GB0524788D0
(en)
*
|
2005-12-05 |
2006-01-11 |
Affibody Ab |
Polypeptides
|
US8278094B2
(en)
|
2005-12-14 |
2012-10-02 |
The Invention Science Fund I, Llc |
Bone semi-permeable device
|
US20110172826A1
(en)
*
|
2005-12-14 |
2011-07-14 |
Amodei Dario G |
Device including altered microorganisms, and methods and systems of use
|
US8682619B2
(en)
|
2005-12-14 |
2014-03-25 |
The Invention Science Fund I, Llc |
Device including altered microorganisms, and methods and systems of use
|
US8734823B2
(en)
|
2005-12-14 |
2014-05-27 |
The Invention Science Fund I, Llc |
Device including altered microorganisms, and methods and systems of use
|
US20110183319A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with microorganisms
|
US20090053790A1
(en)
|
2006-01-31 |
2009-02-26 |
Ishihara Sangyo Kaisha, Ltd. |
Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell
|
US20120035438A1
(en)
|
2006-04-12 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Path selection by a lumen traveling device in a body tub tree based on previous path
|
US8936629B2
(en)
|
2006-04-12 |
2015-01-20 |
Invention Science Fund I Llc |
Autofluorescent imaging and target ablation
|
JP2009539346A
(ja)
*
|
2006-05-26 |
2009-11-19 |
ワイカトリンク リミテッド |
Obフォールドドメイン
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
KR20090088852A
(ko)
|
2006-09-05 |
2009-08-20 |
메다렉스, 인코포레이티드 |
골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
|
PL2066351T3
(pl)
|
2006-10-02 |
2016-02-29 |
Squibb & Sons Llc |
Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie
|
US20080096233A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Robotti Karla M |
Isolation Of Immune Complexes
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
NZ578064A
(en)
|
2006-12-01 |
2012-01-12 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
US7989216B2
(en)
*
|
2006-12-08 |
2011-08-02 |
General Electric Company |
Two helix binders
|
US7977118B2
(en)
*
|
2006-12-08 |
2011-07-12 |
General Electric Company |
Two helix binders
|
US8198043B2
(en)
*
|
2006-12-08 |
2012-06-12 |
General Electric Company |
Two helix binders
|
US7981691B2
(en)
*
|
2006-12-08 |
2011-07-19 |
General Electric Company |
Two helix binders
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
KR20090088946A
(ko)
|
2006-12-14 |
2009-08-20 |
메다렉스, 인코포레이티드 |
씨디70에 결합하는 인간 항체 및 이의 용도
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
WO2008118601A2
(en)
*
|
2007-02-27 |
2008-10-02 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Radiolabeled affibody molecules
|
WO2008124632A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Amphiphilic compound assisted nanoparticles for targeted delivery
|
GB0708376D0
(en)
*
|
2007-05-01 |
2007-06-06 |
Alligator Bioscience Ab |
Novel polypeptides and uses thereof
|
JP2010529127A
(ja)
|
2007-06-05 |
2010-08-26 |
イエール ユニバーシティ |
受容体型チロシンキナーゼの阻害物質およびその使用方法
|
SG149759A1
(en)
|
2007-07-10 |
2009-02-27 |
Millipore Corp |
Media for affinity chromatography
|
EP2183275B1
(de)
|
2007-08-03 |
2014-10-29 |
Affibody AB |
Igf-1r bindende peptide und deren verwendung
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
EP2200634B1
(de)
|
2007-09-21 |
2015-02-11 |
The Regents of The University of California |
Interferon-target zeigt starke apoptotische und antitumorale wirkungen
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
GB2453589A
(en)
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
EP2215268B1
(de)
*
|
2007-11-30 |
2018-08-29 |
Siemens Healthcare Diagnostics Inc. |
Adiponectin-rezeptorfragmente und verwendungsverfahren
|
US9187535B2
(en)
|
2007-12-19 |
2015-11-17 |
Affibody Ab |
Polypeptide derived from protein A and able to bind PDGF
|
EP2077272A1
(de)
|
2007-12-21 |
2009-07-08 |
Affibody AB |
Polypeptid-Bibliothek mit vorbestimmtem Gerüst
|
EP2072525A1
(de)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
Neue Polypeptide mit Bindungsaffinität für HER2
|
CN101945892B
(zh)
*
|
2007-12-26 |
2017-11-24 |
生物测试股份公司 |
用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
|
CA2710453C
(en)
|
2007-12-26 |
2019-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
WO2009080831A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
CA2710471C
(en)
*
|
2007-12-26 |
2018-06-05 |
Biotest Ag |
Immunoconjugates targeting cd138 and uses thereof
|
EP3498307A1
(de)
|
2008-04-02 |
2019-06-19 |
Georgia State University Research Foundation, Inc. |
Kontrastmittel, verfahren zur herstellung von kontrastmitteln und abbildungsverfahren
|
WO2010009391A1
(en)
|
2008-07-18 |
2010-01-21 |
Bristol-Myers Squibb Company |
Compositions monovalent for cd28 binding and methods of use
|
US20100061976A1
(en)
*
|
2008-07-24 |
2010-03-11 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
|
US20100022497A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
|
US20100022991A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and device for maintaining physiological levels of steroid hormone in a subject
|
US20100022494A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
|
EP3629022A1
(de)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Proteinscreeningverfahren
|
NZ590634A
(en)
|
2008-08-05 |
2012-07-27 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
US8592555B2
(en)
|
2008-08-11 |
2013-11-26 |
Emd Millipore Corporation |
Immunoglobulin-binding proteins with improved specificity
|
US20110177154A1
(en)
*
|
2008-09-15 |
2011-07-21 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Tubular nanostructure targeted to cell membrane
|
US20100136094A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100136096A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100137843A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Delivery devices for modulating inflammation
|
US20100135983A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-inflammatory compositions and methods
|
US20100136095A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100136097A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100137246A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-inflammatory compositions and methods
|
US20110295088A1
(en)
|
2008-12-04 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems, devices, and methods including implantable devices with anti-microbial properties
|
JP5985826B2
(ja)
|
2008-12-16 |
2016-09-06 |
ノバルティス アーゲー |
酵母ディスプレイ系
|
US20120165650A1
(en)
|
2010-12-22 |
2012-06-28 |
General Electric Company |
Her2 binders
|
SG195555A1
(en)
|
2008-12-24 |
2013-12-30 |
Emd Millipore Corp |
Caustic stable chromatography ligands
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
US8758324B2
(en)
|
2010-03-05 |
2014-06-24 |
The Invention Science Fund I, Llc |
Device for actively removing a target cell from blood or lymph of a vertebrate subject
|
US8317737B2
(en)
*
|
2009-02-25 |
2012-11-27 |
The Invention Science Fund I, Llc |
Device for actively removing a target component from blood or lymph of a vertebrate subject
|
US8430831B2
(en)
*
|
2009-02-25 |
2013-04-30 |
The Invention Science Fund I, Llc |
Device, system, and method for controllably reducing inflammatory mediators in a subject
|
US8246565B2
(en)
|
2009-02-25 |
2012-08-21 |
The Invention Science Fund I, Llc |
Device for passively removing a target component from blood or lymph of a vertebrate subject
|
BRPI1009232B1
(pt)
|
2009-03-05 |
2022-05-03 |
E.R. Squibb & Sons, Llc. |
Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
|
GB0904355D0
(en)
|
2009-03-13 |
2009-04-29 |
Imp Innovations Ltd |
Biological materials and uses thereof
|
WO2010111509A1
(en)
|
2009-03-25 |
2010-09-30 |
Life Technologies Corporation |
Discriminatory positive/extraction control dna
|
WO2010120514A2
(en)
*
|
2009-03-31 |
2010-10-21 |
The Trustees Of The University Of Pennsylvania |
Antigen-binding proteins comprising recombinant protein scaffolds
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
SG10201401604VA
(en)
|
2009-04-20 |
2014-08-28 |
Oxford Biotherapeutics Ltd |
Antibodies Specific To Cadherin-17
|
EP2422199B1
(de)
|
2009-04-23 |
2018-07-25 |
Siemens Healthcare Diagnostics Inc. |
Monomere und dimere formen von adiponectin-rezeptorfragmenten sowie verwendungsverfahren dafür
|
AR076402A1
(es)
|
2009-04-27 |
2011-06-08 |
Novartis Ag |
Composiciones y metodos para aumentar el crecimiento muscular
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
US8063636B2
(en)
*
|
2009-05-29 |
2011-11-22 |
The Invention Science Fund I, Llc |
Systems, devices, methods, and compositions including targeted ferromagnetic structures
|
US8058872B2
(en)
|
2009-05-29 |
2011-11-15 |
The Invention Science Fund I, Llc |
Systems, devices, methods, and compositions including functionalized ferromagnetic structures
|
US20100303733A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems, devices, methods, and compositions including ferromagnetic structures
|
US8106655B2
(en)
*
|
2009-05-29 |
2012-01-31 |
The Invention Science Fund I, Llc |
Multiplex imaging systems, devices, methods, and compositions including ferromagnetic structures
|
US8154285B1
(en)
|
2009-05-29 |
2012-04-10 |
The Invention Science Fund I, Llc |
Non-external static magnetic field imaging systems, devices, methods, and compositions
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
WO2011018421A1
(en)
|
2009-08-10 |
2011-02-17 |
Morphosys Ag |
Novel screening strategies for the identification of binders
|
US9024766B2
(en)
*
|
2009-08-28 |
2015-05-05 |
The Invention Science Fund, Llc |
Beverage containers with detection capability
|
US8898069B2
(en)
*
|
2009-08-28 |
2014-11-25 |
The Invention Science Fund I, Llc |
Devices and methods for detecting an analyte in salivary fluid
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
WO2011047087A2
(en)
|
2009-10-13 |
2011-04-21 |
Nanostring Technologies, Inc. |
Protein detection via nanoreporters
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
CN102640001A
(zh)
|
2009-11-05 |
2012-08-15 |
诺瓦提斯公司 |
预测纤维化进展的生物标记物
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
JP5798125B2
(ja)
*
|
2009-12-15 |
2015-10-21 |
チェ,ムヒョン |
単量体に結合特異性がある結合体の反復鎖と多数単量体の複合体内での架橋結合の生成増加を通じた二量体及び多量体の生産方法
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
KR20180053775A
(ko)
|
2010-04-23 |
2018-05-23 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
EP2566894A1
(de)
|
2010-05-06 |
2013-03-13 |
Novartis AG |
Zusammensetzungen und verfahren zur verwendung von therapeutischen mehrwertigen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
|
NZ603829A
(en)
|
2010-05-06 |
2015-03-27 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
NO2933262T3
(de)
|
2010-07-09 |
2018-09-29 |
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CN103154032A
(zh)
|
2010-08-13 |
2013-06-12 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
MY162825A
(en)
|
2010-08-20 |
2017-07-31 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
WO2012027440A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
WO2012044992A2
(en)
|
2010-09-30 |
2012-04-05 |
Agency For Science, Technology And Research (A*Star) |
Methods and reagents for detection and treatment of esophageal metaplasia
|
EP2625203A1
(de)
|
2010-10-05 |
2013-08-14 |
Novartis AG |
Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
|
CN103403020A
(zh)
*
|
2010-12-21 |
2013-11-20 |
Jsr株式会社 |
蛋白a的新型耐碱变体及其在亲和色谱中的用途
|
CN103270044B
(zh)
|
2010-12-21 |
2016-03-09 |
Jsr株式会社 |
亲和色谱用载体和分离免疫球蛋白的方法
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
CN103703143B
(zh)
|
2011-01-31 |
2016-12-14 |
爱普瑞斯生物公司 |
鉴定细胞中的多个表位的方法
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
AR085138A1
(es)
|
2011-02-04 |
2013-09-11 |
Genentech Inc |
VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
|
US20140088019A1
(en)
|
2011-02-11 |
2014-03-27 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
CA2834983C
(en)
|
2011-05-06 |
2020-11-17 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
PL3498732T3
(pl)
|
2011-05-06 |
2022-02-28 |
Zoetis Services Llc |
Przeciwciała przeciw czynnikowi wzrostu nerwów oraz sposoby ich otrzymywania i zastosowania
|
JP6258194B2
(ja)
|
2011-05-06 |
2018-01-10 |
ネックスヴェット オーストラリア プロプライエタリー リミテッド |
抗神経成長因子抗体並びに前記の製造及び使用方法
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
SG10201604559TA
(en)
|
2011-06-08 |
2016-07-28 |
Emd Millipore Corp |
Chromatography matrices including novel staphylococcus aureus protein a based ligands
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
NZ618503A
(en)
|
2011-06-28 |
2016-03-31 |
Oxford Biotherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
JP6113721B2
(ja)
|
2011-06-28 |
2017-04-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
治療標的及び診断標的
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
EP2742953B1
(de)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutikum für autoimmunerkrankungen mit pd-1-agonist
|
MX359384B
(es)
|
2011-10-11 |
2018-09-25 |
Genentech Inc |
Conjunto mejorado de anticuerpos bisespecificos.
|
ES2769786T3
(es)
|
2011-10-14 |
2020-06-29 |
Recordati Ag |
Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
|
EP2784159B1
(de)
|
2011-11-25 |
2018-05-09 |
SNU R&DB Foundation |
Cis-regulierendes element aus hepatitis-b-virus und dessen verwendung
|
CN104159924B
(zh)
|
2011-12-05 |
2018-03-16 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
MX358680B
(es)
|
2011-12-08 |
2018-08-31 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a cd138.
|
EP2794656B1
(de)
|
2011-12-21 |
2019-02-27 |
Novartis AG |
Zusammensetzungen die gegen faktor p und c5 gerichtete antikörper enthalten
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
US9808502B2
(en)
|
2012-02-20 |
2017-11-07 |
Swedish Orphan Biovitrum Ab (Publ) |
Polypeptides binding to human complement C5
|
CA2865243A1
(en)
|
2012-02-23 |
2013-08-29 |
President And Fellows Of Harvard College |
Modified microbial toxin receptor for delivering agents into cells
|
JP2015512902A
(ja)
|
2012-03-28 |
2015-04-30 |
アフィボディ・アーベー |
経口投与
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
WO2014013016A1
(en)
|
2012-07-20 |
2014-01-23 |
Affibody Ab |
Method for determining the her2 status of a malignancy
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2882868B1
(de)
|
2012-08-08 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Dynamikbereichssteigerung zur identifikation mehrerer epitope in zellen
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN111763247A
(zh)
|
2012-09-25 |
2020-10-13 |
阿菲博迪公司 |
白蛋白结合多肽
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
MX368067B
(es)
|
2012-12-05 |
2019-09-18 |
Novartis Ag |
Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
|
EP2931293B1
(de)
|
2012-12-12 |
2019-02-20 |
University Of Virginia Patent Foundation |
Zusammensetzungen und verfahren zur regulierung der erythropoiese
|
JP5904565B2
(ja)
|
2012-12-27 |
2016-04-13 |
国立研究開発法人産業技術総合研究所 |
微小タンパク質の骨格構造に基づく分子ライブラリ
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
PT2953969T
(pt)
|
2013-02-08 |
2019-12-03 |
Novartis Ag |
Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
CA3175634A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
US9944700B2
(en)
|
2013-03-13 |
2018-04-17 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
GB201311031D0
(en)
*
|
2013-06-20 |
2013-08-07 |
Queen Mary & Westfield College |
Method
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
AR097102A1
(es)
|
2013-08-02 |
2016-02-17 |
Pfizer |
Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco
|
TN2016000057A1
(en)
|
2013-08-14 |
2017-07-05 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015069459A1
(en)
|
2013-11-05 |
2015-05-14 |
Novartis Ag |
Organic compounds
|
EP3087101A4
(de)
|
2013-12-20 |
2017-12-06 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
WO2015091957A1
(en)
|
2013-12-20 |
2015-06-25 |
Affibody Ab |
Engineered albumin binding polypeptide
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EP3140392B1
(de)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Herstellung von heteromultimeren proteinen mittels säugerzellen
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
PE20170287A1
(es)
|
2014-08-07 |
2017-04-05 |
Novartis Ag |
Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
|
EP3194437B1
(de)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3234602B1
(de)
|
2014-12-19 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Verfahren zur identifizierung mehrerer epitope in ausgewählten subpopulationen von zellen
|
US10632193B2
(en)
|
2014-12-24 |
2020-04-28 |
Neximmune, Inc. |
Nanoparticle compositions and methods for immunotherapy
|
DK3280432T3
(da)
|
2015-04-06 |
2021-04-26 |
Subdomain Llc |
Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cells
|
TN2017000417A1
(en)
|
2015-06-05 |
2019-01-16 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
CA2993009A1
(en)
|
2015-07-31 |
2017-02-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
CN115043944A
(zh)
|
2015-08-03 |
2022-09-13 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
EP3347377B1
(de)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
|
EP3365027B1
(de)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
JP2018535224A
(ja)
|
2015-11-19 |
2018-11-29 |
アスクレピクス セラピューティクス エルエルシー. |
抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
CN109069623A
(zh)
|
2015-12-18 |
2018-12-21 |
诺华股份有限公司 |
靶向CD32b的抗体及其使用方法
|
US10626383B2
(en)
|
2016-01-15 |
2020-04-21 |
Thermo Fisher Scientific Baltics Uab |
Thermophilic DNA polymerase mutants
|
CN109071632B
(zh)
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
CA3016849A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
KR20170108203A
(ko)
|
2016-03-16 |
2017-09-27 |
주식회사 피플바이오 |
응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
AU2017259794B2
(en)
|
2016-05-02 |
2023-04-13 |
Encodia, Inc. |
Macromolecule analysis employing nucleic acid encoding
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
EP3455240A1
(de)
|
2016-05-11 |
2019-03-20 |
GE Healthcare BioProcess R&D AB |
Verfahren zum speichern einer trennmatrix
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
US11753438B2
(en)
|
2016-05-11 |
2023-09-12 |
Cytiva Bioprocess R&D Ab |
Method of cleaning and/or sanitizing a separation matrix
|
EP3455243B1
(de)
|
2016-05-11 |
2021-03-24 |
Cytiva BioProcess R&D AB |
Trennmatrix
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
WO2017194782A2
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
US11236141B2
(en)
|
2016-05-13 |
2022-02-01 |
Orionis Biosciences BV |
Targeted mutant interferon-beta and uses thereof
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CN110381988A
(zh)
|
2016-06-15 |
2019-10-25 |
诺华股份有限公司 |
使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
|
EA201990868A1
(ru)
|
2016-10-04 |
2019-09-30 |
Асклепикс Терапьютикс, Инк. |
СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2
|
CN110114368A
(zh)
|
2016-10-24 |
2019-08-09 |
奥睿尼斯生物科学公司 |
靶向突变干扰素-γ及其用途
|
WO2018111782A1
(en)
|
2016-12-12 |
2018-06-21 |
Cepheid |
Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
|
IL308980A
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods of their use
|
CA3049105A1
(en)
|
2017-01-04 |
2018-07-12 |
Lauren O. Bakaletz |
Dnabii vaccines and antibodies with enhanced activity
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
EP3577133A1
(de)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Gezielte chimäre proteine und verwendungen davon
|
EP3580230A1
(de)
|
2017-02-07 |
2019-12-18 |
VIB vzw |
Auf immunzellen gerichtete bispezifische chimäre proteine und verwendungen davon
|
KR102572663B1
(ko)
|
2017-02-08 |
2023-09-01 |
노파르티스 아게 |
Fgf21 모방 항체 및 이의 용도
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
AU2018236271B2
(en)
|
2017-03-15 |
2023-12-21 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
WO2018175460A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
KR102014056B1
(ko)
*
|
2017-04-18 |
2019-08-27 |
앱클론(주) |
단백질의 순도 및 항원에 대한 친화성이 향상된 폴리펩티드, 이의 항체 또는 항원 결합 단편과의 복합체, 및 이들의 제조방법
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019002178A1
(en)
|
2017-06-26 |
2019-01-03 |
Thermo Fisher Scientific Baltics Uab |
DNA MUTANTS THERMOPHILIC POLYMERASES
|
JP2020525421A
(ja)
|
2017-06-28 |
2020-08-27 |
ノバルティス アーゲー |
尿失禁を予防及び治療するための方法
|
WO2019028427A1
(en)
|
2017-08-03 |
2019-02-07 |
Asclepix Therapeutics, Llc. |
METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
|
EP3700933A1
(de)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
|
AU2018358057B2
(en)
|
2017-10-31 |
2023-03-02 |
Encodia, Inc. |
Kits for analysis using nucleic acid encoding and/or label
|
MX2020004933A
(es)
|
2017-11-14 |
2021-01-08 |
Arcellx Inc |
Polipéptidos que contienen dominios d y sus usos.
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
SG11202003168WA
(en)
|
2017-11-14 |
2020-05-28 |
Arcellx Inc |
Multifunctional immune cell therapies
|
EP3713965A1
(de)
|
2017-11-22 |
2020-09-30 |
Novartis AG |
Reverse bindemittel für anti-faktor-xi/xia-antikörper und verwendungen davon
|
WO2019122200A1
(en)
|
2017-12-22 |
2019-06-27 |
Thermo Fisher Scientific Baltics Uab |
Polymerase chain reaction composition comprising amines
|
WO2019152979A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
JP2021517907A
(ja)
|
2018-04-18 |
2021-07-29 |
アブクロン・インコーポレイテッドAbclon Inc. |
スイッチ分子及びスイッチャブルキメラ抗原受容体
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
EP3626265A1
(de)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-cd45rc-antikörper und verwendungen davon
|
EP3856779A1
(de)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Chimäre cd22-antigen-rezeptor(car)-therapien
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
CA3114925A1
(en)
|
2018-10-05 |
2020-04-09 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for enzymatic disruption of bacterial biofilms
|
TW202039586A
(zh)
|
2018-12-18 |
2020-11-01 |
瑞士商諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
US11248046B2
(en)
|
2019-02-15 |
2022-02-15 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
GB201903233D0
(en)
|
2019-03-08 |
2019-04-24 |
Oxford Genetics Ltd |
Method of selecting for antibodies
|
US20220154174A1
(en)
|
2019-03-08 |
2022-05-19 |
Oxford Genetics Limited |
Method of Selecting for Antibodies
|
CN114144433A
(zh)
|
2019-03-22 |
2022-03-04 |
反射制药有限公司 |
用于目标蛋白的多价d-肽化合物
|
KR20220044612A
(ko)
|
2019-03-22 |
2022-04-08 |
리플렉시온 파마슈티컬스, 인크. |
Vegf에 대한 d-펩티드성 화합물
|
CN114072499A
(zh)
|
2019-04-30 |
2022-02-18 |
Encodia 公司 |
用于制备分析物的方法和相关试剂盒
|
WO2020234399A1
(en)
|
2019-05-20 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Pd−1/cd3二重特異性タンパク質による血液がん治療
|
CA3145385A1
(en)
|
2019-07-08 |
2021-01-14 |
Steven D. Goodman |
Antibody compositions for disrupting biofilms
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
WO2021058795A2
(en)
|
2019-09-27 |
2021-04-01 |
Stark Labs |
Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
JP2023518538A
(ja)
|
2020-03-20 |
2023-05-02 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
ヒトcd45rcに特異的なキメラ抗原受容体およびその使用
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
KR102502287B1
(ko)
|
2020-04-17 |
2023-02-22 |
앱클론(주) |
항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
|
JP2023525053A
(ja)
|
2020-05-12 |
2023-06-14 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
KR102350655B1
(ko)
|
2020-10-13 |
2022-01-12 |
인센 주식회사 |
테스토스테론-특이적 어피바디 및 이의 용도
|
WO2022081779A1
(en)
|
2020-10-13 |
2022-04-21 |
Avitide LLC |
Affinity ligand libraries of three-helix bundle proteins and uses thereof
|
US20240002522A1
(en)
|
2020-11-20 |
2024-01-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Anti-cd25 antibodies
|
EP4247496A1
(de)
|
2020-11-20 |
2023-09-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Anti-cd25-antikörper
|
CA3202358A1
(en)
|
2020-12-16 |
2022-06-23 |
Andreas BOSSHART |
Novel slow-release prodrugs
|
WO2022178396A1
(en)
|
2021-02-19 |
2022-08-25 |
Avitide LLC |
Aav2 affinity agents
|
JP2024509890A
(ja)
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
プロテアーゼ切断可能なプロドラッグ
|
CA3211248A1
(en)
|
2021-03-09 |
2022-09-15 |
Nina RESCHKE |
Novel darpin based cd33 engagers
|
EP4304729A1
(de)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Neuartige darpin-basierte cd123-engager
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|